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MYC protein expression scoring and its impact on
the prognosis of aggressive B-cell lymphoma
patients 
This study examined the reproducibility of MYC and
BCL-2 immunohistochemical scoring as well as the
impact of higher expression of both proteins (double
expressor status, DE) on survival and progression in a
large retrospective cohort of aggressive B-cell lymphoma
patients treated with rituximab plus cyclophosphamide,
doxorubicin, vincristine and prednisone (R-CHOP) or R-
CHOP-like regimens with a median follow up of 67
months (range 0-138). We also investigated possible
MYC protein expression cut offs with the highest repro-
ducibility among pathologists and predictability of gene
translocation. We showed that immunohistochemistry
(IHC) for MYC and BCL-2 is highly reproducible when
cut-off values of >70% for MYC and >50% for BCL-2 are
used. This threshold not only predicts the presence of
rearrangements (with respect to MYC), but is also clini-
cally valuable. In fact, it identifies a subset of patients
who are poor responders and who may benefit from
alternate therapeutic strategies.
Several investigators have demonstrated that diffuse
large B-cell lymphomas (DLBCL) with MYC and BCL-2
double expression (DE-LBCL) have adverse prognosis
when treated by conventional immunochemotherapies.1
Therefore, evaluation of MYC and BCL-2 protein expres-
sion by IHC is an important tool in the prognostic strati-
fication of patients.2 Although expression of MYC-IHC in
≥40% neoplastic cells and the BCL-2 in ≥50% have been
indicated as prognostically significant cut offs in many
reports, among hematopathologists, some disagreement
about these thresholds remains.3,4 Standardizing cut offs
to define positivity for MYC-IHC and BCL-2-IHC with
higher reproducibility and prognostic impact is thus high-
ly desirable in order to optimize patient management.5,6 
We analyzed 753 aggressive B-cell lymphoma patients.
These included: Burkitt lymphomas (BL, n=223); DLBCL
not otherwise specified (DLBCL-NOS, n=456); high
grade B-cell lymphomas (HGBCL) with MYC and BCL-2
and/or BCL-6 rearrangement [HG double hit (HGDH),
n=51, including 8 blastoid, 16 diffuse monomorphic and
27 intermediate morphology]; and HGBCL, NOS
(n=23).7-9 All cases belonging to these categories, except
for BL, will be referred to hereon as non-BL. The follow-
ing clinical data were collected for non-BL: sex, age at
diagnosis, ECOG performance status, stage (Ann Arbor),
lactate dehydrogenase (LDH) level, International
Prognostic Index (IPI), bulky disease, extranodal versus
nodal, bone marrow involvement. Original MYC-IHC
and BCL-2-IHC slides were re-evaluated by 3 trained
pathologists blinded as to the original scores. Although
aware that immunohistochemical interpretation may be
affected by technical issues, we intentionally decided not
to re-stain all slides in only one laboratory, but instead to
confront original slides from different laboratories which
apply different unmasking procedures and use different
clones on a “real-life” basis (Table 1). Scores were report-
ed in 5% intervals rounded up to the nearest 10%. Any
discrepancies in MYC-IHC and BCL-2-IHC scoring was
resolved by consensus on a multi-head microscope until
an agreement of >95% concordance was reached.
Discrepancy was defined as 10% deviation. Our findings
confirm that BCL-2-IHC scoring is highly reproducible
across the different institutions and that a ≥50% cut off is
reliably assessable [agreement >90%; k=0.97; standard
error (SE):=0.018; 95% confidence interval (CI): 0.765-
0.901]. On the contrary, scoring MYC-IHC staining was
confirmed to be critical, mainly because of the variability
of staining intensity, percentage of positivity, presence of
necrosis and crush artifacts. Concordance was high only
for MYC-IHC positivity >70%, while a larger discrepan-
cy was observed in the range 40-69%10 (Figure 1). The lat-
ter can have a crucial impact on clinical decision making
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Table 1. Immunohistochemical and FISH analysis of MYC* and BCL-2* proteins and genes in the different institutions.
MYC clone/source MYC antigen retrieval/dilution BCL-2 clone/source BCL-2 antigen retrieval/dilution
Berlin EP121, Pressure cooker, 124, Agilent, Germany Pressure cooker, 
Epitomics, Germany citrate buffer pH 6.0 citrate buffer pH 6.0
Bologna EP121, Epitomics, Milan PT link 92°C /1:100 124, Agilent, Milan PT link 90°C /1:100
Firenze Y69, Roche, Milan Ready to use SP124, Roche, Milan Ready to use
London Y69, Abcam, UK Ready to use 124, Dako, UK PT link 90°C /1:100
Siena & Nairobi Y69, Roche, Milan Ready to use SP124, Roche, Milan Ready to use
MYC BAP probe/source MYC FUSION probe/source BCL-2 BAP probe/source
Berlin Split Signal MYC, Agilent, Dual  fusion IGH/MYC, Zytomed, Splits Signal BCL-2, Agilent,
Germany Germany Germany
Bologna ZytoLight  SPEC MYC Dual Color ZytoLight SPEC MYC/IgH ZytoLight SPEC BCL-2 Dual Color 
Break Apart Probe, Bio-Optica, Dual Color Dual Fusion Probe , Bio-Optica, Break Apart Probe, Bioptica, 
ZitoVision GmbH, Germany ZitoVision GmbH, Germany ZitoVision GmbH, Germany
Firenze ZytoLight  SPEC MYC Dual Color ZytoLight SPEC MYC/IgH Dual Color ZytoLight SPEC BCL-2 Dual Color
Break Apart Probe, Bio-Optica, Dual Fusion Probe, Bio-Optica, Break Apart Probe, Bioptica, 
ZitoVision GmbH, Germany ZitoVision GmbH, Germany ZitoVision GmbH, Germany
London Kreatech, Leica, UK Kreatech, Leica, UK Kreatech, Leica, UK
Siena & NairobiZytoLight  SPEC MYC Dual Color Break Apart Probe, Bio-Optica, ZitoVision GmbH, Germany ZytoLight SPEC MYC/IgH Dual Color Dual Fusion Probe, Bio-
Optica, ZitoVision GmbH, GermanyZytoLight SPEC BCL-2 Dual Color Break Apart Probe, Bioptica, ZitoVision GmbH, Germany. *On 4 m thick formalin-fixed paraffin-embed-
ded sections; BAP: break-apart probe.
and patient care, as well as on the comparison between
different studies. Therefore, we propose the threshold of
MYC-IHC 70-100% to define non-BL cases with high
expression of MYC and 0-39% to classify samples with
low expression of MYC protein. Samples with MYC-IHC
scores between 40% and 69% could not be categorized
as MYC protein negative or positive with acceptable
accuracy in routine practice and should be termed as
cases with intermediate MYC expression. Moreover, we
suggest scoring should preferably be defined on moder-
ately to strongly stained nuclei and in hot spot areas, if
present. After revision, in the non-BL series, prevalence
of DE-LBCL as defined by the cut offs proposed by the
literature (MYC-IHC ≥40% and BCL-2-IHC ≥50%) was
32% (n=176/530);7 of these 100 showed MYC-IHC
≥70% (DE 70% in the following).
A second end point of this study was to investigate the
relation between MYC-IHC and MYC gene alterations,
trying to identify parameters potentially applicable in a
value-for-money approach. When using the threshold of
MYC-IHC ≥80% in BL and ≥70% in non-BL, around 99%
BL and 88% non-BL cases with MYC rearrangements can
be predicted. Therefore, considering the high correlation
between MYC gene rearrangement and MYC protein
expression in BL, FISH analysis could theoretically be
limited to cases with atypical morphology and/or
immunophenotype and MYC-IHC <80%. In non-BL, a
cut off of MYC-IHC ≥70% would identify cases at higher
probability of MYC rearrangement. However, it should
be noted that roughly 10% of HGDH have a lower
expression of MYC; in these cases, FISH should be rec-
ommended.11 
The third end point was to perform a survival analysis
in cases of HGDH, DE, nonDH/nonDE patients for
whom overall survival (OS) and progression-free survival
(PFS) data were available. HGDH lymphomas are known
to be very aggressive neoplasms that do not respond to
standard therapy and they have a  dismal prognosis.12
However, it has recently  been reported that the adverse
prognosis may be mitigated by other factors such as lack
of BCL-2 protein, and absence/low MYC protein expres-
sion.5 The clinical significance of MYC-IHC and BCL-2-
IHC expression has been extensively studied but the
results have not been consistent; hence, there is still no
clear use for  protein expression evaluation in the clin-
ic.13,14
Univariate Cox analysis showed that the factors signif-
icantly associated with OS and PFS were: age [Odds
Ratio (OR): 4.8% each year; confidence interval (CI):
1.03-1.066; P<0.001], LDH >150 UI/L (OR: 187%, CI:
1.756-4.715; P<0.001), IPI (OR: 71%, CI: 1.422-2.056;
P<0.001), bone marrow involvement (OR: 86.2%, CI:
1.102-3.145; P=0.02), MYC translocation (OR: 71%, CI:
1.281-2.297; P<0.001), BCL-2 translocation (OR: 97%,
CI: 1.389-2.795; P=0.002), MYC-IHC ≥70% (OR: 65%,
CI: 0.22-0.539; P<0.001), DH status (OR: 310%, CI:
2.529-6.662; P<0.001), DE 70% status (OR: 61.5%, CI:
1.976-2.67; P=0.04). Stepwise multivariate analysis
demonstrated that IPI (OR: 62.2%, CI: 1.225-2.146;
P=0.001), MYC-IHC ≥70% (OR: 224.8%, CI: 1.714-
6.155; P<0.001), DH status (OR: 131.7%, CI: 1.003-
5.350; P=0.049), DE 70% status (OR: 177.5%, CI: 1.020-
1.080; P=0.006) were independent prognostic factors that
influence patients' outcome. 
A comparison of HGDH, DE-LBCL [according to World
Health Organization (WHO) criteria,  i.e. MYC-IHC
≥40% and BCL-2-IHC ≥50%] and nonDH/nonDE sub-
sets of non-BL in terms of OS and PFS confirmed that
HGDH patients showed significantly worse survival than
the other two groups (P<0.001; χ2 39.24 for OS and 13.13
for PFS) (Figure 2A and Online Supplementary Figure S1A). 
By stratifying DE-LBCL according to MYC protein
expression (70-100%, 40-69%,) the prognosis turned out
to be poorer in the former (P<0.001, χ213.152 for OS and
10.723 for PFS) (Figure 2B and Online Supplementary Figure
S1B). 
Dividing HGDH cases according to MYC protein posi-
tivity revealed that those with MYC-IHC ≥70% had a
worse prognosis than cases with MYC-IHC ≤69%
(P<0.001, χ248.215 for OS and 35.549 for PFS) (Figure 2C
and Online Supplementary Figure S1C). This  supports
prior observations that patients with MYC rearrange-
ments or DH lymphomas devoid of MYC-IHC expres-
sion might exhibit less aggressive clinical behaviors.13 
Given that the highest concordance and reproducibility
of MYC-IHC was >70%, we compared OS and PFS of
DE-LBCL showing MYC-IHC >70% and BCL-2-IHC
>50% with HGDH cases; we found no significant differ-
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Figure 1. Graph of original and revised MYC immunohisto-
chemistry (IHC) scores. The percentage of cases with con-
cordance (white bars) or discordance (black bars) after
MYC IHC revision for the three ranges is shown. The con-
cordance analysis results are listed. SE: standard error; CI:
confidence interval.
ences in prognosis (P=0.2, χ20.777 for OS and 3.441 for
PFS) (Figure 2D and Online Supplementary Figure S1D).
Interestingly, the OS and the PFS of HGBCL, NOS
strictly depended on MYC expression being 30 and 28
months in HGBCL, NOS with MYC 40-69%, 10 and 14
months in those with MYC 70-100%. 
These findings again highlight the need to establish
more widely reproducible cut-off values for IHC assays
with higher predictive value, to safely stratify high-risk
patients. Moreover, they may also, at least in part,
explain the above mentioned inconsistencies in pub-
lished data. 
Finally, since the cell-of-origin (COO) classification of
LBCL exerts a prognostic impact, with non-GCB lym-
phomas showing a poorer prognosis than GCB ones, we
stratified HGDH and DE-LBCL according to COO
defined by Hans' algorithm.15 A poorer prognosis was
demonstrated only in patients with MYC-IHC ≥70%,
with no differences according to  the COO. However, no
conclusions can be drawn due to both the limited num-
ber of cases examined per group and  to the IHC assess-
ment of COO  which is known to misclassify a subset of
samples. 
Different molecular mechanisms may be responsible
for the same disease entity and neoplastic phenotype.
FISH currently represents the gold standard for identify-
ing rearrangements, but it is not capable of detecting
genetic deregulation affecting gene expression at tran-
scriptional and post-transcriptional levels that might
result in protein overexpression and neoplastic transfor-
mation.4 Our results support the role of MYC protein as
the active trigger of the MYC-mediated oncogenic effects
since protein expression levels likely represent a more
direct measure of the activity of a particular gene16 and
MYC-IHC should be undertaken in all cases. However,
the last WHO criteria assessed that MYC staining is not
reliable enough to select cases for FISH analysis.7
According to our results, the cut off of MYC-IHC ≥70%,
based both on reproducibility among pathologists and
clinical impact, is a good indicator of underlying MYC
gene rearrangement. Nonetheless, our promising data
need further validation in an independent cohort of
patients. In addition, given the highest scoring efficiency,
the cut offs of MYC-IHC ≥70% and BCL-2-IHC ≥50%
could be applied when FISH is not available (due to issues
of practicability, cost, short turn-around-time, quality
control) to select a subset of patients who are poor
responders and who may benefit from alternate thera-
peutic strategies. 
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Figure 2. Kaplan-Meier curves of overall survival (OS) in the different patient groups. (A) Kaplan-Meier curve of OS in double hit (DH) versus double expressor
(DE) versus non-double hit/non-double expressor (nonDH/nonDE) lymphomas.  There was a significant difference in OS  between the DH and the other two
groups (log rank test, P<0.001). DH lymphomas were defined by having both MYC and BCL-2 rearrangements; DE were characterized by showing MYC-immuno-
histochemistry (IHC) ≥40% and BCL-2-IHC ≥50%; nonDH/nonDE included cases without double hits or with one only single hit, and with none or only one protein
expression between MYC and BCL-2. (B) Kaplan-Meier curve of OS in DE depending on MYC protein expression. OS was significantly lower in the group showing
MYC-IHC ≥70% than in the group with MYC-IHC 40-69% (log rank test, P<0.001) indicating that a MYC-IHC ≥70% cut off defines a clinically relevant subgroup
of DE cases. (C) Kaplan-Meier curve of OS in DH depending on MYC protein expression. There was a significant difference in OS  between the two groups (MYC-
IHC 0-69% and BCL-2-IHC ≥50%, and MYC-IHC ≥70% and BCL-2-IHC ≥50%) with MYC ≥70% cases having the lower survival rate (log rank test, P<0.001).
Noteworthy, among HGDH with MYC-IHC 0-69%, the 3 cases showing MYC-IHC <40% had a mean OS of 44 months (data not shown). These findings indicate
that adverse survival in HGDH is highly impacted by high MYC-IHC expression (≥70%). (D) Kaplan-Meier curve of OS in DH versus DE as defined by MYC-IHC
≥70% and BCL-2-IHC ≥50% versus nonDH/nonDE. OS overlaps in DH and DE with MYC-IHC ≥70% and BCL-2-IHC ≥50% (log rank test, P=0.2 for DH versus DE
with MYC ≥70% and BCL-2-IHC ≥50%;), this is worse than the OS of the nonDH/nonDE (log rank test, P<0.001 for either DH or DE with MYC ≥70% and BCL-2-
IHC ≥50% versus nonDH/nonDE). 
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